neck (8) , and will be used for treatment of additional cancers in the future. On the other hand, in patients with advanced stage melanoma, objective response rates of nivolumab were 43.7% and median progression-free survival was 6.9 months (9) . Overall mortality and recurrence rates, however, remain high in the patients treated with immune checkpoint inhibitors. There is great interest in identifying biomarkers that will allow the selection of patients who would respond to nivolumab because of the associated substantial side effects and treatment costs. We therefore examine the possibility of daily blood examination laboratory data as new biomarkers.
Materials and Methods

Patient material
Enrolled in this study were sixteen patients with unresectable malignant melanoma, who were treated with nivolumab in Department of Dermatology, Wakayama Medical University, between September 2014 and March 2017. Excluded were patients with single nivolumab treatment and those with inflammatory diseases, such as rheumatoid arthritis, which could affect laboratory data. Nivolumab dose was fixed at 2 mg/kg every three weeks in 13 patients or 3 mg/kg every two weeks in the remaining three patients.
Patient characteristics are summarized in Table 1 . Mean age was 71.3 years (range, 48-87), and 43.8% (n = 7) were male. Performance status (PS) was 0 to 1 in 93.8% (n = 15) of patients, while 56.3% (n = 9) of patients had stage IV disease. According to Curtin classification (10), clinical subtypes of primary lesions were as follows: 43.8% (n = 7) of mucosal melanoma, 25% (n = 4) of acral melanoma, 18.8% (n = 3) of melanoma arising from non-chronically sun-damaged (non-CSD), 6.3% (n = 1) of melanoma arising from chronically sun-damaged (CSD), and 6.3% (n = 1) of unknown. Metastasis was found in lymph node (n = 10, 62.5%), lung (n = 5, 31.3%), skin (n = 3, 18.8%), mesenterium (n = 3, 18.8%), liver (n = 2, 12.5%), digestive tract (n = 2, 12.5%), or other sites (bone, brain, kidney and adrenal glands). As prior treatment, primary lesions were surgically removed in 81.3% patients (n = 13). Additional treatment, including dacarbazine chemotherapy (n = 7, 43.8%), interferon (IFN)-β local injection (n = 2, 12.5%), and radiotherapy, (n = 2, 12.5%) was performed in 50% (n = 8) of patients.
Clinical assessment
Response assessment based on response evaluation criteria in solid tumor (RECIST) v1.1 was performed, and patients were classified into responder groups (Partial Response: PR) + Stable Disease: SD) or non-responder groups (Progressive Disease: PD). Laboratory data in this study was obtained before nivolumab treatment and approximately one month before first imaging assessment (average 77.4 days after first administration of nivolumab). Examined were: white blood cell count (WBC), by electric resistance method), absolute lymphocyte counts (ALC, by flow cytometry method), absolute neutrophil count (ANC, by flow cytometry method), absolute monocyte count (AMC, by flow cytometry method), absolute eosinophil count (AEC, by flow cytometry method), and absolute basophil count (ABC, by flow cytometry method), as well as levels of lactate dehydrogenase (LDH, by JSCC standardization compliance law), C-reactive protein (CRP, by latex immunization turbidity method), one hour value of erythrocyte sedimentation rate (ESR, by light beam detection method), and 5-S-cysteinydopa (5-S-CD, by HPLC method). This study protocol was approved by the Wakayama Medical University Ethical Committee.
Statistical analysis
Statistics were calculated using single-factor analysis of variance (ANOVA) and repeated measure ANOVA for comparison of median. p < 0.05 was considered statistically significant. Receiver operating characteristic (ROC) curve analysis was also performed using GraphPad Prism software ® . ECOG: Eastern Cooperative Oncology Group, Non-CSD: melanoma arising from non-chronically sun-damaged, CSD: melanoma arising from chronically sun-damaged, IFN-β: interferon-β.
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The best response rates were PD in nine patients (56.3%), SD in five patients (31.3%) and PR in two patients (12.5%). Most patients showed no change in the response after the first evaluation, except for one patient whose response changed from SD into PD after about one year.
Baseline levels of candidates for biomarkers
First, we examined whether baseline laboratory data before treatment can predict response to nivolumab. Blood counts, LDH, CRP, ESR, and 5-S-CD were regarded as candidates. Patients were classified into responder groups (PR+SD) and non-responder groups (PD), according to RECIST v1.1. In the responder
Results
Side effects and clinical responses
Immunology-related adverse events that occurred in our patients were as follows: vitiligo (n = 3), psoriaform rash (n = 2), interstitial pneumonia (n = 1, grade 3), hypothyroidism (n = 1, grade 2), thrombocytopenia (n = 1, grade 3), stomatitis (n = 1, grade 3), and nausea (n = 1, grade 3). Laboratory data abnormalities including liver enzymes and renal function were also found, although they were all grade 1 and asymptomatic. In three patients, nivolumab administration was discontinued after experience of grade 3 interstitial pneumonia, grade 2 hypothyroidism, or grade 3 nausea. 
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www.biosciencetrends.com (Figure 1, left) . There were no other significant differences between these groups (Table 2) . We then performed ROC curve analysis to compare the clinical usefulness of above baseline biomarkers for nivolumab treatment (Figure 1, right) . Areas under curve (AUC) of baseline ESR, CRP, or ALC were 0.89 (95% CI, 0.68 to 1.09), 1.00 (95% CI, 1.00 to 1.00) or 0.86 (95% CI, 0.66 to 1.06), respectively. AUC of baseline CRP level was higher than those of other markers.
Changes of levels of biomarker candidates in the responder group during treatment
Increase or decrease of candidate levels after nivolumab treatment as novel biomarkers for response rate prediction were then evaluated. Laboratory data was obtained approximately one month before the first imaging assessments. In the responder group (PR+SD), there were significant differences in the levels of CRP, ESR, ANC, and ALC; ALC levels were significantly increased, while other levels were decreased after nivolumab treatment compared with the baseline (p = 0.027, 0.012, 0,018, and 0.018, respectively) ( Figure  2, left) . Changes of other laboratory data are shown in Table 3 .
In ROC curve analysis, AUC of CRP, ESR, ANC, or ALC was 1.00 (95% CI, 1.00 to 1.00), 0.85 (95% CI, 0.65 to 1.06), 0.79 (95% CI, 0.56 to 1.02), or 0.83 (95% CI, 0.61 to 1.04), respectively (Figure 2, right) . Accordingly, AUC for CRP level was higher than those for the other biomarkers.
4. Case presentation of a representative patient
In a patient with typical PR course, baseline ESR levels and CRP levels were elevated, and ALC level was reduced before nivolumab treatment ( Figure 3A ). After five courses of nivolumab, levels of CRP, ESR, and ANC were decreased, and ALC level was increased from the baseline. Positron emission tomography (PET) imaging showed the patient's tumor was markedly diminished by nivolumab ( Figure 3B ).
Discussion
Predictive biomarkers for the efficacy of nivolumab treatment against malignant melanoma have been investigated vigorously in recent years. For example, soluble CD73 levels (11) or Th9 cell number (12) in peripheral blood, expression levels of PD-L1 (13) or MHC-II (14) in tumor cells, as well as number of CD8 positive T cells (15) or specific inflammation and IFN-γ related mRNA-based signatures in infiltrating immune cells have been reported as clinically useful biomarkers. Furthermore, Nakamura et al. described serum LDH and CRP levels to be baseline prognostic markers in patients with advanced melanoma treated with nivolumab (16). They also indicated that patients with increased ALC and decreased ANC during nivolumab therapy had significantly better overall survival. In this study, we determined the possibility that treatment efficacy of nivolumab can be predicted by daily blood examination. Responder group showed significantly higher baseline levels of ESR or CRP and significantly lower ALC level before the nivolumab treatment. In addition, nivolumab treatment decreased the levels of CRP, ESR, and ANC, while it increased ALC level in responder group. According to the ROC curve, CRP was most effective of these to distinguish responder group from non-responder group both before and during treatment. Patients with elevated baseline CRP levels before treatment will respond to nivolumab, and normalization of the elevated CRP by nivolumab indicates that the patients are the responder before the first imaging assessment.
Taken together, we firstly reported ESR is also the baseline biomarker of the efficacy of nivolumab. We confirm that CRP is also useful to predict efficacy both before and during treatment. CRP is suggested to be the most effective biomarker in daily blood examination using ROC curve analysis. There is a possibility that inflammation responses, reflected by elevated CRP and ESR, may be activated in the responder group before nivolumab treatment, and they are normalized during the treatment. Nivolumab treatment may therefore be more effective for malignant melanoma with strong inflammation.
Link between inflammation and cancer has been reported for over 150 years. Virchow firstly reported the association by observing white blood cells around the cancer cells in 1881 (17) . Increased CRP has been reported to be an independent prognostic marker for malignant melanoma (18) , correlating with the number of lymph node metastases (19) . Indication of the association of elevated ESR with short survival has also been reported (20) . PD-1 is expressed on effector T cells only after an immune response, such as infection or inflammation (15) . Especially, its expression is especially remarkable on effector T cells invading the peripheral inflamed tissues. The extent of the immune response against malignant tumors usually varies depending on general condition of the patients or type of malignant tumors. Considering the inflammatory markers (CRP and ESR) in the responder group were higher before treatment, these patients have more baseline PD-1 expression due to strong immune response. Our study also suggests the synergistic effect of nivolumab therapy combined with existing treatments that causes inflammation (such as IFN-β local injection or radiation therapy).
Our study also showed increased ALC and decreased ANC levels during nivolumab therapy correlated with the better response. Neutrophil-lymphocyte ratio (NLR) is a known marker of systemic host inflammation, and it is reported that the increased NLR is associated with poor prognosis in several malignant tumors, including malignant melanoma (21, 22) , consistent with the previous paper and current study. On the other hand, lower baseline ALC before the treatment in the responder group, which was found in this study, is contradictory to this hypothesis, and may be because of the small number of patients. As the limitation, this study is retrospective study of only 16 patients. For earlier and more efficient prediction of the efficacy, the clinical significance of the combination of levels of CRP/ESR and other inflammatory markers should be evaluated in larger number of patients.
